Catherine Skari
-
Jan- 2024 -18 JanuaryNews
MYELODYSPLASTIC SYNDROMES | Advantages of Iron Chelation Revealed in Analysis of Low-Risk MDS
A recent groundbreaking study sheds new light on the effectiveness of iron chelation therapy (ICT) for patients suffering from low-risk…
Read More » -
17 JanuaryNews
BREAKING | Vertex and CRISPR’s Gene-editing Therapy Casgevy Receives Early FDA Approval for β-Thalassaemia Treatment
Just one month prior, Casgevy made history as the first CRISPR gene editing therapy to enter the US market when…
Read More » -
16 JanuaryNews
EXCLUSIVE WEBINAR | Guidelines for the Management of Non-Transfusion Dependent β-Thalassaemia
📌 Webinar Title: Guidelines for the Management of Non-Transfusion Dependent β-Thalassaemia 📌 Date & Time: Friday, February 02, 2024, 15:00…
Read More » -
11 JanuaryNews
Chinese Base Editing Therapy ‘Clinically Cured’ Patient with β-Thalassaemia, Researchers Say
Shanghai-based biotech company CorrectSequence Therapeutics, in collaboration with Guangxi Medical University, has achieved a significant clinical milestone by successfully treating…
Read More » -
8 JanuaryNews
COLD AGGLUTININ DISEASE | ANX1502 Passes Phase 1 Trial, Proving Safe for Healthy Volunteers
Administered orally as a liquid suspension, ANX1502 demonstrated good tolerability, with no serious side effects reported. The drug’s pharmacokinetics also…
Read More » -
2 January
-
Dec- 2023 -27 DecemberNews
A YEAR IN RETROSPECT | Global Public Health Achievements and Challenges in 2023
We applaud the remarkable strides in eradicating diseases and infections, such as ending the COVID-19 public health emergency and intensifying…
Read More » -
22 December
-
19 DecemberNews
wAIHA | Fostamatinib May Induce Durable Hemoglobin Response in Subset of Patients
Interestingly, this positive outcome was predominantly observed among participants hailing from North America, Australia, or Western Europe, while those from…
Read More » -
9 DecemberNews
SICKLE CELL DISEASE | FDA Approves Two Landmark Gene Therapies for the Treatment of the Disorder
The two therapies are Casgevy (exa-cel) by Vertex Pharmaceuticals and CRISPR Therapeutics – the world’s first drug to utilize the…
Read More »

